InsiderSignal.AI

InsiderSignal.ai

PTCT - Ptc Therapeutics, Inc.

Insider Sale by Klein Matthew B. (CEO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

3 days ago, Klein Matthew B., serving as CEO at Ptc Therapeutics, Inc. (PTCT), sold 2,850 shares at $70.91 per share, for a total transaction value of $202,094.00. Following this transaction, Klein Matthew B. now holds 394,070 shares of PTCT.

This sale represents a 1.00% decrease in Klein Matthew B.'s stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, April 21, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 23, 2026, 2 days after the trade was made.

Ptc Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Klein Matthew B.

Klein Matthew B.

CEO

Matthew B. Klein, M.D., M.S., F.A.C.S. is the Chief Executive Officer of PTC Therapeutics, Inc. (PTCT) and a member of its Board of Directors since March 2023.[[1]](https://www.ptcbio.com/team/leadership/matthew-b-klein/)[[3]](https://www.ptcbio.com/leadership/board/matthew-b-klein-m-d-m-s-facs/) He joined PTC in October 2019 as Global Head, Gene and Mitochondrial Therapies, advancing to Global Head, Clinical Development in March 2020, Chief Development Officer in April 2020, and Chief Operating Officer in January 2022.[[1]](https://www.ptcbio.com/team/leadership/matthew-b-klein/)[[3]](https://www.ptcbio.com/leadership/board/matthew-b-klein-m-d-m-s-facs/) Prior to PTC, Dr. Klein served as CEO of BioElectron Technology Corporation from 2018 to 2019, Chief Medical Officer from 2013 to 2019, and Senior Vice President, Clinical Science from 2012 to 2013.[[1]](https://www.ptcbio.com/team/leadership/matthew-b-klein/)[[3]](https://www.ptcbio.com/leadership/board/matthew-b-klein-m-d-m-s-facs/)[[4]](https://www.mitoaction.org/bios/dr-matt-klein/) Earlier, he held the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington.[[4]](https://www.mitoaction.org/bios/dr-matt-klein/) A trained physician, professor of surgery, and public health expert, he earned a BA summa cum laude and Phi Beta Kappa from the University of Pennsylvania, an MD with honors from Yale University School of Medicine, and an MS in epidemiology from the University of Washington School of Public Health.[[1]](https://www.ptcbio.com/team/leadership/matthew-b-klein/)[[3]](https://www.ptcbio.com/leadership/board/matthew-b-klein-m-d-m-s-facs/)[[4]](https://www.mitoaction.org/bios/dr-matt-klein/) Dr. Klein also serves on the boards of PTC Therapeutics International Limited, PTC Therapeutics International Holdings Unlimited Company, and ClearPoint Neuro, Inc.[[1]](https://www.ptcbio.com/team/leadership/matthew-b-klein/)[[3]](https://www.ptcbio.com/leadership/board/matthew-b-klein-m-d-m-s-facs/)

View full insider profile →

Trade Price

$70.91

Quantity

2,850

Total Value

$202,094.00

Shares Owned

394,070

Trade Date

Tuesday, April 21, 2026

3 days ago

SEC Filing Date

Thursday, April 23, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Ptc Therapeutics, Inc.

Company Overview

No company information available
View news mentioning PTCT

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5881257

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime